Growth Metrics

Ligand Pharmaceuticals (LGNDZ) Convertible Debt (2018 - 2022)

Ligand Pharmaceuticals (LGNDZ) has disclosed Convertible Debt for 8 consecutive years, with $176.5 million as the latest value for Q1 2022.

  • Quarterly Convertible Debt fell 49.89% to $176.5 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $176.5 million through Mar 2022, down 49.89% year-over-year, with the annual reading at $320.7 million for FY2021, 27.49% down from the prior year.
  • Convertible Debt hit $176.5 million in Q1 2022 for Ligand Pharmaceuticals, down from $320.7 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $639.0 million in Q4 2019 to a low of $176.5 million in Q1 2022.
  • Historically, Convertible Debt has averaged $474.6 million across 5 years, with a median of $452.3 million in 2020.
  • Biggest five-year swings in Convertible Debt: increased 4.77% in 2019 and later crashed 49.89% in 2022.
  • Year by year, Convertible Debt stood at $609.9 million in 2018, then rose by 4.77% to $639.0 million in 2019, then plummeted by 30.78% to $442.3 million in 2020, then dropped by 27.49% to $320.7 million in 2021, then tumbled by 44.95% to $176.5 million in 2022.
  • Business Quant data shows Convertible Debt for LGNDZ at $176.5 million in Q1 2022, $320.7 million in Q4 2021, and $316.9 million in Q3 2021.